Get startedLog in
    Picture of Roche Holding AG logo

    ROP — Roche Holding AG News Story

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Roche Says Phase III Celestimo Study Meets Primary Endpoint In Follicular Lymphoma

    Picture of Roche Holding AG logoRoche Holding AG
    17/09/2026 06:07
    BRIEF-Roche Says Phase III Celestimo Study Meets Primary Endpoint In Follicular Lymphoma
    Sept 17 (Reuters) - ROCHE HOLDING AG ROPC.S:
    • LUNSUMIO-BASED REGIMEN SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL IN FOLLICULAR LYMPHOMA IN PHASE III CELESTIMO STUDY
    • PHASE III CELESTIMO STUDY MEETS PRIMARY ENDPOINT IN FOLLICULAR LYMPHOMA
    • CELESTIMO STUDY SHOWS SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL
    • NO NEW SAFETY SIGNALS IDENTIFIED FOR LUNSUMIO AND LENALIDOMIDE COMBINATION
    • CELESTIMO STUDY DATA TO BE SUBMITTED TO HEALTH AUTHORITIES
    Source text: ID:nGNE1qfyFQ
    Further company coverage: ROPC.S

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 587785269;))

    Recent news on Roche Holding AG

    See all news